Latest news with #Co.
Bangkok Post
an hour ago
- Business
- Bangkok Post
Coway Boosts Thai Red Cross with Health Support
Bangkok, July 30, 2025 – Coway (Thailand) Co., Ltd., the leading water and air purifier brand from South Korea, has reinforced its commitment to the health and well-being of Thai communities by establishing a dedicated service booth at the National Blood Service Centre of the Thai Red Cross Society. The booth provides clean drinking water, tissues, and ready-to-eat meals for daily blood donors, offering comfort and care to those supporting a vital public service. The launch was attended by Mr Kiryong Choi, Chief Executive Officer of Coway (Thailand) Co., Ltd., and Ms Piyanun Kumkrong, Assistant Director of Blood Procurement and Corporate Image at the National Blood Centre, Thai Red Cross Society. As part of the initiative, Coway also donated three high-performance Coway Giant air purifiers to improve indoor air quality in donor service areas and staff workspaces. This contribution aims to support a cleaner, safer environment for both the public and healthcare professionals, enhancing the overall donor experience while aligning with the Thai Red Cross Society's critical mission. 'Coway is dedicated to improving the lives of Thai people not only through our premium health products but also through meaningful community initiatives that create a lasting impact,' said Mr Kiryong Choi. 'This is especially important in times of challenge or crisis. Today's contribution reflects our commitment to public health and to helping Thai society grow stronger.' The initiative aligns with Coway's 'Best Life Solution Company' vision, which strives to promote physical, mental, and emotional well-being in a sustainable and holistic manner. Through ongoing partnerships with Thailand's public and private sectors, Coway continues to support the country's healthcare infrastructure. The company also plans to expand its community outreach efforts, reinforcing its mission to conduct business while actively improving lives.
&w=3840&q=100)
First Post
a day ago
- Sport
- First Post
‘Rohit and Kohli retired, Bumrah can't play all five Tests...': Ashwin gives Ben Stokes reality check after Manchester drama
Ravichandran Ashwin gave England a reality check and also slammed Ben Stokes and his team over their reaction during the final day of the fourth Test in Manchester. Stokes tried to walk off after offering a draw while Indian batters Ravindra Jadeja and Washington Sundar were nearing centuries. read more Ashwin has slammed Ben Stokes & Co. over the drama in Manchester Test. YT-Ashwin/Reuters Former India all-rounder Ravichandran Ashwin has hit out at England after the controversy that unfolded during the final day of the fourth Test in Manchester, giving a strong reality check to Ben Stokes' side. Speaking on his YouTube channel Ash Ki Baat, Ashwin reminded everyone that India played the series with several setbacks, including the retirement of senior players Virat Kohli and Rohit Sharma, and key injuries. 'Rohit and Kohli retired, Bumrah can't play all five Tests, and a few players were dropped. If England were in such a position coming into the series, would they have even put up a fight? Definitely not,' Ashwin said. STORY CONTINUES BELOW THIS AD It is important to note that Nitish Kumar Reddy and Akash Deep were forced out of the playing XI in the fourth Test due to an injury, while reserve bowler Arshdeep Singh was also ruled out after suffering a blow to his left thumb. While Arshdeep is expected to make his debut in the fifth Test at The Oval, Reddy and Akash Deep are out of the series. Meanwhile, Rishabh Pant fractured his toe in the fourth Test and has been ruled out of the London match. Ashwin's comments come in the aftermath of a heated moment on Day 5 in Manchester, when England captain Ben Stokes tried to call off the match midway through India's second innings. At the time, Ravindra Jadeja and Washington Sundar were batting and both were close to scoring centuries. Stokes offered a handshake, implying the match be declared a draw, but the Indian batters declined. Ashwin criticised England's attitude and called it hypocritical. 'Have you heard the term double standards? They played your bowlers all day, batted you out, and suddenly, when they're nearing hundreds, you want to walk off? Why should they?' he asked. He further questioned why England were upset. 'You ask, 'You want to make a hundred against Harry?' Not Brook, brother. He has to make a hundred. Bring any bowler - they won't object. Why Brook? Call Steve Harmison, call Andrew Flintoff for all we care. It was your call to bring Brook, not ours.' STORY CONTINUES BELOW THIS AD 'There were two reasons - one, you didn't want to tire your bowlers. Fine. Second, you were frustrated and thought 'If I'm not happy, you shouldn't be either.' Boss, your frustration is not our problem. That's not how cricket works. These are Test runs. A century is earned, not gifted. Washington deserved it, Jadeja deserved it. Period.'
USA Today
a day ago
- Sport
- USA Today
North Carolina 4-star S Marquis Bryant plans to attend Notre Dame's home game against USC
The buzz surrounding Notre Dame's recruiting efforts is only going to get louder when top recruits attend Fighting Irish games this fall. One top prospect who plans to be in attendance for the October 18 battle against USC in South Bend is Marquis Bryant, who was extended an offer by Marcus Freeman and Co. back in March on Pot of Gold Day. The Class of 2027 Rolesville (Rolesville, NC) safety is a four-star prospect and the 13th-best player nationally at his position, per the 247Sports Composite Rankings. The 5-foot-11, 190-pounder visited Notre Dame in mid-June, and he told that he expects to take in the Trojans-Irish battle. ND does have some competition, though, as Bryant also plans to be at Clemson on August 30 and Georgia on September 13. Florida State is another program he wants to visit later this year. But Bryant did say the Irish are "pretty high" on his board, so we'll see how his recruitment ultimately shakes out. Contact/Follow us @IrishWireND on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Notre Dame news, notes and opinions. Follow Dave on X: Miller_Dave
Hindustan Times
2 days ago
- Sport
- Hindustan Times
Ben Stokes' actions called ‘premature' as ex-England star bashes hosts for stump mic antics: ‘Shame to dwell on it'
Ben Stokes and Co. faced backlash from former England cricketer Mark Ramprakash for their antics during the Manchester Test against India. On the final day, India battled with grit to save the match, as Ravindra Jadeja and Washington Sundar held their ground with unwavering focus, both nearing well-deserved centuries. When Stokes suggested ending the game in a draw, Jadeja refused, opting to play on. The decision visibly rattled the English side, who resorted to sledging, while their bowlers showed little intensity, seemingly conserving energy rather than pushing for a result. Ben Stokes and Co. have been put under the scanner for their antics in Manchester.(AFP) Stokes, who was miffed with the Indian batters' response said, 'Jaddu, do you want to get a Test 100 against Brook & Duckett?' Jadeja responded and said, 'What do you want me to do, just walk off?' Zak Crawley, who stood close to the pitch, was heard saying: 'You can, just shake your hand.' Ramprakash was critical of the words the English team used on the stump mic and said it's a shame to dwell on such things. 'The stump microphone and words don't reflect well on Ben Stokes' team, who, let's be fair, are doing a fantastic job of reinvigorating Test cricket. They are playing wonderfully well. The cricket has been on such high class that it is a shame to dwell on it,' said Ramprakash to Sky Sports. Jadeja and Sundar were batting 89 and 80, respectively, when Stokes offered to shake hands for declaration. The two batters decided to continue and completed their century before they eventually settled for a draw. He further questioned what England would have done if one of their players had been in a similar situation batting in the 90s. 'You have to wonder if England had a player on 90 not out, would we have continued. We hear about England players being very proud on being on the honour boards at Lord's and other grounds because those milestones are huge achievements. I can understand where India were coming from,' he said. 'Ben Stokes was possibly a bit premature' Ramprakash further called Stokes' decision to settle for a draw at that stage premature. He also highlighted how the moment was particularly significant for Sundar, who was on the cusp of his maiden Test century, and for Jadeja, who has also been in sublime form this series. 'I think Ben was possibly a bit premature going up (to the Indian batters) in the way he did. It has to be agreed by the opposition captain. India had one player, Washington Sundar, who hadn't got a hundred before and I know that England side like to not think about milestones but for that player, he may never get there again. It was quite a big moment for him. And equally for Jadeja to try and get another Test hundred. They kind of earned the right to stay on, I suppose, from their point of view,' he said.
Business Upturn
3 days ago
- Business
- Business Upturn
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Business Wire India Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: . Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
